MINIMUM INHIBITORY CONCENTRATION QUALITY-CONTROL GUIDELINES FOR BIAPENEM, DU-6859A, FK-037, LEVOFLOXACIN, GREPAFLOXACIN, AND CEFTIZOXIME WHEN USING VARIOUS NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS SUSCEPTIBILITY TEST METHODS

被引:5
作者
BALE, MJ
JONES, RN
ERWIN, ME
MURRAY, PR
WASHINGTON, JA
GERLACH, EH
THORNSBERRY, C
HINDLER, J
DOERN, GV
机构
[1] UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242
[2] WASHINGTON UNIV,BARNES HOSP,ST LOUIS,MO 63110
[3] CLEVELAND CLIN FDN,CLEVELAND,OH 44195
[4] ST FRANCIS REG MED CTR,WICHITA,KS 67214
[5] INST MICROBIOL RES,FRANKLIN,TN
[6] UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024
[7] UNIV MASSACHUSETTS,WORCESTER,MA 01605
关键词
D O I
10.1016/0732-8893(94)90054-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Several multilaboratory collaborative studies using broth microdilution and agar dilution (gonococcal tests only) methods of susceptibility testing were performed to establish quality-control (QC) guidelines. Replicate dilution tests with multiple lots of media were performed with National Committee for Clinical Laboratory Standards recommended QC strains (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212, and Staphylococcus aureus ATCC 29213) by using the following antimicrobials: biapenem, DU-6859a, FK-037, levofloxacin, and grepafloxacin. In addition QC MIC ranges, using appropriate medium modification for Haemophilus influenzae ATCC 49247 and Neisseria gonorrhoeae ATCC 49226 were reported on four (DU-6859a, FK-037, levofloxacin, and grepafloxacin) and two (ceftizoxime and FK-037) antimicrobials, respectively.
引用
收藏
页码:65 / 68
页数:4
相关论文
共 9 条
[1]   CEFTIZOXIME INTERPRETIVE CRITERIA FOR IN-VITRO SUSCEPTIBILITY TESTS WITH NEISSERIA-GONORRHOEAE [J].
BARRETT, MS ;
JONES, RN ;
ERWIN, ME .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (09) :2531-2532
[2]   STATISTICAL CRITERIA FOR SELECTING QUALITY-CONTROL LIMITS FOR BROTH MICRODILUTION SUSCEPTIBILITY TESTS WITH 39 DIFFERENT ANTIMICROBIAL AGENTS [J].
BARRY, AL ;
FUCHS, PC ;
JONES, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (05) :413-420
[3]   INVITRO AND INVIVO ANTIBACTERIAL ACTIVITIES OF LEVOFLOXACIN (L-OFLOXACIN), AN OPTICALLY-ACTIVE OFLOXACIN [J].
FU, KP ;
LAFREDO, SC ;
FOLENO, B ;
ISAACSON, DM ;
BARRETT, JF ;
TOBIA, AJ ;
ROSENTHALE, ME .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :860-866
[4]   ANTIMICROBIAL ACTIVITY OF THE NEW CARBAPENEM BIAPENEM COMPARED TO IMIPENEM, MEROPENEM AND OTHER BROAD-SPECTRUM BETA-LACTAM DRUGS [J].
SADER, HS ;
JONES, RN .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1993, 12 (05) :384-391
[5]   INVITRO ACTIVITY OF OPC-17116 COMPARED TO OTHER BROAD-SPECTRUM FLUOROQUINOLONES [J].
SADER, HS ;
ERWIN, ME ;
JONES, RN .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1992, 11 (04) :372-381
[6]   ANTIMICROBIAL ACTIVITY OF DU-6859, A NEW POTENT FLUOROQUINOLONE, AGAINST CLINICAL ISOLATES [J].
SATO, K ;
HOSHINO, K ;
TANAKA, M ;
HAYAKAWA, I ;
OSADA, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (07) :1491-1498
[7]   MULTICENTER COMPARISON OF IN-VITRO ACTIVITIES OF FK-037, CEFEPIME, CEFTRIAXONE, CEFTAZIDIME, AND CEFUROXIME [J].
WASHINGTON, JA ;
JONES, RN ;
GERLACH, EH ;
MURRAY, PR ;
ALLEN, SD ;
KNAPP, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1696-1700
[8]  
1992, TENTATIVE GUIDELINE
[9]  
1990, APPROVED STANDARD M7